Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group Study

Pratt, Charles B.; Maurer, Harold M.; Gieser, Peter; Salzberg, A.M.; Rao, Bhaskar N.; Parham, David M.; Thomas, Patrick R.; Marcus, Robert B.; Cantor, Alan; Pick, T; Green, Daniel; Neff, James R.; Jenkins, Jesse J.

doi:10.1002/(sici)1096-911x(199804)30:4<201::aid-mpo1>3.0.co;2-k

Cited by 87 publications

(71 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 500 children diagnosed with nonrhabdomyosarcoma soft-tissue sarcoma (NRSTS) each year in the United States represent only 4% of all malignant tumors in the pediatric population (1). Most pediatric soft-tissue sarcomas are rhabdomyosarcomas (2); however, 40% of children <5 years and 77% aged 15-19 years will have NRSTS (1). This group of tumors comprises many different histologic types.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant Radiotherapy for Pediatric and Young Adult Nonrhabdomyosarcoma Soft-Tissue Sarcoma

Smith

Indelicato

Knapik

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Adjuvant Radiotherapy for Pediatric and Young Adult Nonrhabdomyosarcoma Soft-Tissue Sarcoma

Smith

Indelicato

Knapik

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

“…Three patients received chemotherapy according to SIOP -MMT protocols for STS (branch for non-rhabdo) [12][13][14]. Response was variable.…”

Section: Discussionmentioning

confidence: 99%

Synovial sarcoma in children. A single centre experience

et al. 2007

View full text Add to dashboard Cite

Synovial sarcoma (SS) is a rare disease in the paediatric population, predominating in adolescents. Surgery remains the best treatment strategy for resectable cases. Adjuvant chemotherapy or radiotherapy can be used but have not proven efficacy. Metastatic disease and unsuccessful surgery are major prognostic factors. We describe four cases in children aged 7-13 years old. All of them were affected by SS of upper and lower limbs, and had satisfactory resections with different outcomes in spite of receiving diverse chemotherapy regimens. One of them is at the moment under treatment for relapse, two are disease-free and another died after metastatic disease.

show abstract

“…As reported by Treuner et al [33], patients treated according to the guidelines of a protocol showed better prognosis than those treated with major protocol violations or those with recurrence when entered into a trial. Recently, Pratt et al [34] demonstrated that in metastatic NRSTS, combination therapy with vincristine, Adriamycin, actinomycin D, and cyclophosphamide with or without dacarbazine did not offer any advantage in terms of eventfree survival. But Walter et al [35] developed an aggressive ifosfamide-based treatment approach to children with NRSTS and showed improvement in tumor control.…”

Section: Discussionmentioning

confidence: 99%

THE ROLE OF CHEMOTHERAPY IN CHILDHOOD SOFT TISSUE SARCOMAS OTHER THAN RHABDOMYOSARCOMAS: Experience of the Northern Israel Oncology Center

Weyl

Arush

Nahum

et al. 1999

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Forty-three children with nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) were treated at the Northern Israel Oncology Center in Haifa, Israel, from 1971 to 1996. The male:female ratio was 1.5:1 and the median age of patient was 10 years (range, 3 months-18 years). The most common histopathologic diagnoses were fibrosarcoma (32.5%) and synovial sarcoma (16%). The sites of primary tumor were lower limb (35%), trunk (18%), upper limb (16%), head and neck (16%), and retroperitoneum (11%). By Intergroup Rhabdomyosarcoma Study classifications, 13 patients presented as group I, 15 patients as group II, 10 patients as group III, and 5 patients as group IV. Median follow-up time was 63 months (range, 6 months-18 years). The estimated survival after a 5-year period is 72% (SE +/- 17) for patients in group I, 75 +/- 15% in group II, 90 +/- 9% for patients in group III, and 40 +/- 21% for patients in group IV. Eleven patients relapsed; 4/6 who developed local relapse were cured and are alive with disease, while 4/5 who developed distant metastases are dead. For the 28 patients who underwent complete resection at diagnosis, the estimated survival after a 5-year period is 87 +/- 5% vs. 60 +/- 17% for the 15 patients who underwent partial excision or biopsy. Local radiotherapy was delivered after surgery to group III patients. Preoperative and postoperative chemotherapy was delivered to the patients of groups III and IV, and postoperative chemotherapy only to group II patients. Chemotherapy produced demonstrable gain in survival for group II and III patients but not for patients with metastases. The authors conclude that an aggressive surgical approach is needed in patients with NRSTS. Chemotherapy may help as a preoperative treatment in bulky disease or as a postoperative treatment for microscopic residual disease.

show abstract

Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group Study

Cited by 87 publications

References 36 publications

Adjuvant Radiotherapy for Pediatric and Young Adult Nonrhabdomyosarcoma Soft-Tissue Sarcoma

Adjuvant Radiotherapy for Pediatric and Young Adult Nonrhabdomyosarcoma Soft-Tissue Sarcoma

Synovial sarcoma in children. A single centre experience

THE ROLE OF CHEMOTHERAPY IN CHILDHOOD SOFT TISSUE SARCOMAS OTHER THAN RHABDOMYOSARCOMAS: Experience of the Northern Israel Oncology Center

Contact Info

Product

Resources

About